Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05728918
Other study ID # A-111-091
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 1, 2023
Est. completion date April 30, 2024

Study information

Verified date February 2024
Source Greenyn Biotechnology Co., Ltd.
Contact Ming-Shun Wu, MD
Phone +886-229307930
Email mswu@tmu.edu.tw
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to assess the effect of Antrodia cinnamomea mycelia on immune modulation in subhealth people.


Description:

This study aims to assess the effect of Antrodia cinnamomea mycelia on immune modulation in subhealth people: a randomized, double-blind, placebo-controlled, and parallel clinical investigation.


Recruitment information / eligibility

Status Recruiting
Enrollment 29
Est. completion date April 30, 2024
Est. primary completion date February 29, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 50 Years to 75 Years
Eligibility Inclusion Criteria: - Subjects are easy to feel fatigued - Subjects have poor sleep quality Exclusion Criteria: - Pregnant women or preparing for pregnancy. - Lactating women. - Women gave birth 6 months before the study. - Poor kindy and livers funcitons - Severe cardiovascular or other chronic diseases - Alcohol abuser - Using immune-associated supplements

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Antrodia cinnamomea mycelia
Antrodia cinnamomea mycelia capsule, two capsules/day (600 mg/day) for 3 months
Placebo
Placebo capsule, two capsules/day (600 mg/day) for 3 months

Locations

Country Name City State
Taiwan WanFang Hospital Taipei

Sponsors (1)

Lead Sponsor Collaborator
Greenyn Biotechnology Co., Ltd.

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Immune analysis Changes in T cell markers of 29 participants will be analyzed between baseline and week 4. Baseline up to 4 weeks
Primary Immune analysis Changes in B cell markers of 29 participants will be analyzed between baseline and week 4. Baseline up to 4 weeks
Primary Antibody analysis Changes in IgA levels of 29 participants will be analyzed between baseline and week 4. Baseline up to 4 weeks
Primary Antibody analysis Changes in IgD levels of 29 participants will be analyzed between baseline and week 4. Baseline up to 4 weeks
Primary Antibody analysis Changes in IgG levels of 29 participants will be analyzed between baseline and week 4. Baseline up to 4 weeks
Primary Antibody analysis Changes in IgE levels of 29 participants will be analyzed between baseline and week 4. Baseline up to 4 weeks
Primary Antibody analysis Changes in IgM levels of 29 participants will be analyzed between baseline and week 4. Baseline up to 4 weeks
Primary Cytokine analysis Changes in IL-1beta levels of 29 participants will be analyzed between baseline and week 4. Baseline up to 4 weeks
Primary Cytokine analysis Changes in IL-4 levels of 29 participants will be analyzed between baseline and week 4. Baseline up to 4 weeks
Primary Cytokine analysis Changes in IL-6 levels of 29 participants will be analyzed between baseline and week 4. Baseline up to 4 weeks
Primary Cytokine analysis Changes inFN-gamma levels of 29 participants will be analyzed between baseline and week 4. Baseline up to 4 weeks
Primary Cytokine analysis Changes in TNF-alpha levels of 29 participants will be analyzed between baseline and week 4. Baseline up to 4 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05899595 - Effects of a Personalized Physical Training to Reduce Fatigue N/A
Not yet recruiting NCT01154647 - Pain Inhibition in Patients With Rheumatoid Arthritis and Central Sensitivity Syndromes N/A
Completed NCT00375973 - Double Blind Trial of Duloxetine in Chronic Fatigue Syndrome Phase 2/Phase 3
Completed NCT02499302 - Mental Training for CFS Following EBV Infection in Adolescents N/A
Completed NCT02156128 - Subjective Memory Complaints, Objective Memory Performance and Cognitive Training N/A
Not yet recruiting NCT06386133 - Chronic Fatigue in Multiple Sclerosis: MS Copilot Boost Solution Compared to Standard Care N/A
Not yet recruiting NCT05116657 - Obstructive Sleep Apnoea Post Covid 19: Role of the Upper Airway Microbiome
Completed NCT00788918 - Study of Cerebral Function in Patients With Chronic Hepatitis C Infection (HCV/CNS) N/A
Completed NCT04435002 - The Effect of Acupressure on Fatigue in Individuals With Chronic Fatigue Syndrome N/A
Recruiting NCT05778006 - Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis (ME/CFS) Registry and Biobank, COVID-19, SARS-CoV-2
Recruiting NCT06253026 - Fatigue in Air Search and Rescue Missions
Completed NCT00001415 - Glucocorticoid Effects on Cellular Cytokine Release N/A
Completed NCT04797871 - Resistance Training and Clinical Status in Patients With Post Discharge Symptoms After Covid-19 N/A
Recruiting NCT04049331 - Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone Phase 2
Completed NCT02335437 - Chronic Fatigue Following Acute Epstein-Barr Virus Infection in Adolescents N/A
Completed NCT04833673 - The Effects of Relaxation Techniques on Pain, Fatigue and Kinesiophobia in Multiple Sclerosis Patients: A Three Arms Randomized Trial N/A
Recruiting NCT04947488 - Evaluation of the Effects of Treatment With Bioarginin C in Adult Subjects Belonging to the Post-Covid Day Hospital N/A
Recruiting NCT05840237 - REGAIN: RCT of Oxaloacetate for Fatigue in Long COVID N/A
Active, not recruiting NCT04104750 - The Assessment of Fatigue and Quality of Life in Patients With Bone Tumor,
Recruiting NCT03773003 - Research for Pathophysiology of Cancer Related Fatigue (CRF) and Chronic Fatigue (CFS/ME) N/A